Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study
Florence Joly, Michel Fabbro, Dominique Berton, Justine Lequesne, Amélie Anota, Alicja Puszkiel, Anne Floquet, Hélène Vegas, Hugues Bourgeois, L. Bengrine Lefevre, Benoît You, Fanny Pommeret, Alain Lortholary, Dominique Spaëth, Anne‐Claire Hardy‐Bessard, Cyril Abdeddaim, Marie-Christine Kaminsky-Forrett, Michel Tod, Jean‐Emmanuel Kurtz, Francesco Del Piano, Jérôme Meunier, Nadia Raban, Jérôme Alexandre, Marie‐Ange Mouret‐Reynier, I. L. Ray-Coquard, Magali Provansal Gross, Pierre-Emmanuel Brachet
Topics & Concepts
MedicinePazopanibBevacizumabInternal medicinePaclitaxelClinical endpointGastrointestinal perforationMaintenance therapyRandomized controlled trialOncologyChemotherapyGastroenterologyOvarian cancerSurgeryCancerSunitinibPeritonitisOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyAngiogenesis and VEGF in Cancer